- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
Patent holdings for IPC class A61K 31/537
Total number of patents in this class: 455
10-year publication summary
|
38
|
37
|
31
|
36
|
33
|
30
|
50
|
48
|
30
|
16
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Gilead Sciences, Inc. | 2032 |
27 |
| Genentech, Inc. | 3976 |
14 |
| Regeneron Pharmaceuticals, Inc. | 4238 |
12 |
| Genequantum Healthcare (Suzhou) Co., Ltd. | 61 |
12 |
| Amgen Inc. | 4071 |
10 |
| ImmunoGen, Inc. | 400 |
9 |
| Dimerix Bioscience Pty Ltd. | 37 |
8 |
| Merck Sharp & Dohme LLC | 3753 |
8 |
| Novartis AG | 10882 |
7 |
| Bayer AG | 3319 |
7 |
| F. Hoffmann-La Roche AG | 7932 |
6 |
| Boehringer Ingelheim International GmbH | 4705 |
6 |
| Takeda Pharmaceutical Company Limited | 2707 |
6 |
| Bio-Thera Solutions, Ltd. | 124 |
6 |
| Ube Corporation | 345 |
6 |
| Merck Sharp & Dohme Corp. | 2200 |
5 |
| Cellectar Biosciences, Inc. | 27 |
5 |
| Hangzhou DAC Biotech Co., Ltd | 102 |
5 |
| Immunwork Inc. | 25 |
5 |
| Jiangsu Hengrui Medicine Co., Ltd. | 706 |
5 |
| Other owners | 286 |